Indefinite Delivery Contract SPE2DX16D9937

This federal contract IDV award, solicited by the Defense Logistics Agency (DLA), is a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999.99 and held by DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, awarded under the SPE2DX program, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide.

The task orders provided show the prime contractor has fulfilled delivery orders for specialized medications such as Xolair, Trikafta, Keytruda, Botox, and Nucala, as well as various other prescription drugs and medical supplies. These orders, which do not have any set-aside designations, were awarded with firm fixed-price pricing and cover a wide range of medical needs, including oncology treatments, contraceptives, auto-injectors, and specialized pharmaceutical products. The contract has an ultimate completion date of December 31, 2025, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.